Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03122444 · ClinicalTrials.gov registry record · Early Phase 1
Imipramine on ER+ve and Triple Negative Breast Cancer
A Early Phase 1 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 17
- Enrollment target
NCT03122444 is a Early Phase 1 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 17 participants.
The verdict
NCT03122444, a Early Phase 1 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
Comparing changes in biomarkers from a diagnostic core needle biopsy to surgical pathology specimen or repeat core needle biopsy.
Interventions
- DRUG Imipramine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-07-05 |
| Est. Completion | 2022-05-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03122444
The ClinicalTrials.gov registry entry for NCT03122444 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Imipramine is the first listed.
NCT03122444 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03122444 about?
NCT03122444 is a clinical study titled "Imipramine on ER+ve and Triple Negative Breast Cancer". Comparing changes in biomarkers from a diagnostic core needle biopsy to surgical pathology specimen or repeat core needle biopsy.
What is the current status of trial NCT03122444?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 17 participants. The study started on 2019-07-05. Estimated completion is 2022-05-01.
What interventions are being tested in trial NCT03122444?
The interventions under investigation include: Imipramine (DRUG).
Who is sponsoring clinical trial NCT03122444?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.